المؤلفون: John Harrison, Philip D. Harvey, Garen Manvelian, Angele Moryusef, Jonas Mandel, Michel Farnier, Henry N. Ginsberg, M. John Chapman, Marwan N. Sabbagh

المساهمون: Neurology

المصدر: European Heart Journal
Harvey, P D, Sabbagh, M N, Harrison, J E, Ginsberg, H N, Chapman, M J, Manvelian, G, Moryusef, A, Mandel, J & Farnier, M 2018, ' No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: A meta-analysis of individual patient data ', European Heart Journal, vol. 39, no. 5, pp. 374-381 . https://doi.org/10.1093/eurheartj/ehx661
European Heart Journal, 39(5), 374-381. Oxford University Press

مصطلحات موضوعية: Male, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Coronary Artery Disease, 030204 cardiovascular system & hematology, Placebo, Antibodies, Monoclonal, Humanized, LDL, PCSK9, 03 medical and health sciences, 0302 clinical medicine, Cognition, Ezetimibe, Clinical Research, Internal medicine, medicine, Humans, 030212 general & internal medicine, Adverse effect, Alirocumab, Aged, Randomized Controlled Trials as Topic, business.industry, Anticholesteremic Agents, Hazard ratio, Antibodies, Monoclonal, Cholesterol, LDL, Middle Aged, Discontinuation, Patient safety, Female, Cholesterol-lowering drugs, Cognitive function, Nervous System Diseases, Proprotein Convertase 9, Cardiology and Cardiovascular Medicine, business, Neurocognitive, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80c495c73cc4b0556e9c7ca963f8e7c0
http://europepmc.org/articles/PMC5837381

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.